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In the first scenario, three widely known randomised trials on early Class II (2-phase) treatment versus delayed (1-phase) treatment are summarised by a recently updated Cochrane review (Batista et al. 2018) . For this article, the results of two kinds of early treatment (headgear and functional appliances) have been combined into a single group. Setting other trial results aside, the authors followed patients from the start of early treatment (if administered) to the end of fixed appliance treatment and measured the incidence of new dental trauma. The effect of treatment on new trauma risk (=incidence) is here presented as relative risk (RR) with its 95% confidence interval (CI). The RR is the appropriate effect size to express a treatment-induced relative change in risk (Sinclair and Bracken 1994) .
In the second scenario, a long-term randomised trial of early maxillary protraction for Class III treatment compared to no treatment (observation) is presented (Mandall et al. 2016) . The authors followed patients from the start of early treatment (if administered) and assessed at 15 years of age their need for orthognathic surgery through a blinded panel of consultants. The effect of treatment on the need for orthognathic surgery is likewise presented as RR with its 95% CI.
The RRs of treatment-induced effects on dental trauma and need for surgery are given in Table 1 with the corresponding 95% CIs. 
Discussion
The first statement refers to the magnitude of the relative effect size, which is here the RR. The two scenarios have similar RRs (both around 0.6) and with similar uncertainty around them (95% CIs of 0.4-0.9 and 0.3-0.9). The Pvalues are somewhat different, but this can be attributed to different sample sizes in the two scenarios and Pvalues do not give information about the magnitude of an effect anyway. Overall, statement (a) is correct. The second statement refers to the absolute effect size, which is different to the relative effect size. It is recommended that clinical trials report both relative and absolute effects to give a complete picture of the treatment effects and their implications (Moher et al. 2010) . The recommended absolute effect size is the risk difference, which is simply the difference between the two groups' risks. If risk differences are calculated, it is obvious that the absolute effect sizes for the two scenarios differ: −11.4% for the first scenario and −29.3% for the second scenario (Table 2 ) and therefore, statement (b) is false. Even though the relative effects are similar, the absolute effects vary considerably. This has to do with the fact that the patient's baseline (pre-treatment) risk has a direct effect on the absolute gains attained by treatment. This is illustrated in Figures 1 and 2 . We see that the baseline risk for new dental trauma among untreated Class II patients (in these trials) is 29.1%, while the baseline need for orthognathic surgery among untreated Class III patients (in this trial) is 65.6% (Figures 1 and 2 , respectively). Subsequently, early Class II treatment Figure 1 . Illustrative risks of new dental trauma for the scenario of early Class II treatment. 'saves' 11 of every 100 patients from a dental trauma they would have had if left untreated (Figure 1 ; right panel), while early Class III treatment 'saves' 30 of every 100 patients from orthognathic surgery that would be needed if left untreated (Figure 2 ; right panel). In the end and with the same relative effects, the risks (for trauma/surgery) are reduced in both scenarios compared to untreated patients, but both the absolute risk reduction (Figures 1 and 2 ; right panel; green patients) and the risk of treated patients (Figures 1 and 2 ; right panel; blue patients) re different between the two scenarios. So statement (c) is wrong.
Finally, for a given relative effect, the absolute risk reduction is directly linked to the patient's baseline risk. In the first scenario about Class II early treatment, this pertains to a patient's baseline risk for dental trauma. It is known, however, that trauma risk is not uniform across the general population and several factors are linked to increased trauma risks, including among others patient sex, obesity, inadequate lip coverage, increased overjet, and involvement in sport activities (Soriano et al. 2007; Glendor 2009 ). It is reasonable to assume that a normal-weight girl with moderate overjet and adequate lip coverage, who does ballet, will have a lower risk for dental trauma than an obese boy with large overjet and inadequate lip coverage, who plays basketball. As can be seen in Figure 3 , the expected absolute treatment gains for early Class II correction are different for the hypothetical low-risk girl and high-risk boy. Therefore, statement (d) is false, and the expected net gains of treatment rely on the patients one selects to treat.
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